All In Biotech

Drug Trial Radar · NCT05791201

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

7

Actual

Start

May 16, 2023

Primary completion

Mar 12, 2027

Study completion Mar 12, 2027

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Mar 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).

Conditions

  • Type 1 Diabetes

Interventions

  • VX-264Drug

    Allogeneic human stem cell-derived islets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A and Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 up to 24 months
  2. Part B: Change in Peak C-peptide during Mixed-Meal Tolerance Test (MMTT)Time frame: From Baseline and at Day 90

Locations

16 sites in 7 countries. Site status is shown where the registry gives one.

  • UHealth Diabetes Research Institute

    Miami, Florida

  • University of Chicago

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center Montefiore

    Pittsburgh, Pennsylvania

  • University of Wisconsin

    Madison, Wisconsin

  • University of Alberta, Edmonton

    Edmonton, Canada

  • Montreal Clinical Research Institute

    Montreal, Canada

  • Toronto General Hospital (TGH)

    Toronto, Canada

  • Vancouver General Hospital

    Vancouver, Canada

  • Dresden Center for Islet Transplantation

    Dresden, Germany

  • IRCCS Ospedale San Raffaele

    Milan, Italy

  • Leiden University

    Leiden, Netherlands

  • Hopiteaux Universitaires de Geneve

    Geneva, Switzerland

  • Royal Victoria Infirmary

    Newcastle upon Tyne, United Kingdom

  • Churchill Hospital

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.